Humana Inc. (NYSE:HUM – Get Free Report)’s stock price passed below its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $410.26 and traded as low as $384.61. Humana shares last traded at $386.7270, with a volume of 4,154,245 shares trading hands.
Top Humana Stories
These are some of the HUM stories that stood out recently:
- Positive Sentiment: Royal Bank of Canada upgraded Humana to “Outperform,” adding to a generally favorable analyst view of the shares. Royal Bank of Canada Upgrades Humana to Outperform
- Neutral Sentiment: Humana plans a national Gold Card program that will reduce prior-authorization requirements for qualifying providers. The move could ease administrative burdens, though the near-term financial effect is uncertain. Humana launches National Gold Card Program
- Neutral Sentiment: Humana expects some Louisville employees to return to office work in 2027; the policy appears to have limited direct relevance to near-term results. Humana to mandate office work for select Louisville staff
Wall Street Analyst Weigh In
Several research firms recently issued reports on HUM. Truist Financial raised their price target on Humana from $415.00 to $475.00 and gave the stock a “hold” rating in a research report on Monday, October 12th. Morgan Stanley raised Humana from an “underweight” rating to an “overweight” rating in a research note on Friday, October 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Humana in a research report on Thursday, November 12th. Cantor Fitzgerald started coverage on Humana in a research note on Monday. They set an “overweight” rating for the company. Finally, Zacks Research upgraded shares of Humana from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $484.78.
Humana Stock Down 12.8%
The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.61. The company’s fifty day simple moving average is $410.26 and its 200 day simple moving average is $320.44. The firm has a market capitalization of $46.45 billion, a PE ratio of 37.62, a price-to-earnings-growth ratio of 2.11 and a beta of 0.65.
Humana (NYSE:HUM – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.30. The company had revenue of $41.16 billion for the quarter, compared to analysts’ expectations of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. The firm’s revenue for the quarter was up 26.1% on a year-over-year basis. During the same period in the prior year, the firm earned $3.24 earnings per share. Humana has set its FY 2026 guidance at 9.500- EPS. Analysts anticipate that Humana Inc. will post 9.66 earnings per share for the current fiscal year.
Humana Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, January 29th. Shareholders of record on Thursday, December 24th will be issued a $0.8850 dividend. The ex-dividend date of this dividend is Thursday, December 24th. This represents a $3.54 annualized dividend and a yield of 0.9%. Humana’s payout ratio is 34.44%.
Insiders Place Their Bets
In other news, insider Joseph Ventura sold 5,495 shares of the business’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $433.85, for a total value of $2,384,005.75. Following the completion of the transaction, the insider owned 21,910 shares in the company, valued at $9,505,653.50. The trade was a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Humana
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Innovator Capital Management LLC purchased a new stake in Humana in the third quarter worth approximately $2,546,000. Brown Financial Advisors grew its position in Humana by 4.8% in the 3rd quarter. Brown Financial Advisors now owns 1,228 shares of the insurance provider’s stock worth $468,000 after purchasing an additional 56 shares during the period. iSAM Funds UK Ltd bought a new stake in Humana in the 3rd quarter worth approximately $305,000. Integrated Wealth Concepts LLC raised its stake in Humana by 15.1% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 1,279 shares of the insurance provider’s stock valued at $488,000 after buying an additional 168 shares during the last quarter. Finally, Diversify Advisory Services LLC purchased a new stake in Humana during the 3rd quarter valued at $1,148,000. Institutional investors own 92.38% of the company’s stock.
About Humana
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Further Reading
- Five stocks we like better than Humana
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
